PF-Atlas › Clinical Trials › DC-IPF-DE

Dendritic Cell Immunotherapy for IPF — German Centers of Excellence

Autologous DC therapy · Dendritic Cell Immunotherapy · Phase 1/2

Registry ID
DC-IPF-DE
Phase
Phase 1/2
Status
Recruiting
Drug / intervention
Autologous DC therapy
Mechanism
Dendritic Cell Immunotherapy
Sponsor
German University Hospitals
Start
2024-01

About this trial

Autologous DC therapy is evaluated in DC-IPF-DE, a Phase 1/2 idiopathic pulmonary fibrosis study sponsored by German University Hospitals, targeting dendritic cell immunotherapy. Current status: Recruiting.

View DC-IPF-DE on ClinicalTrials.gov →

Explore related

All Autologous DC therapy trialsDendritic Cell Immunotherapy mechanismAll IPF trials
Medical disclaimer. This page summarizes public trial data for DC-IPF-DE for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.